| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP Chief R&D | CMO &EVP Dev &Med Affairs
1 company
Garg Pushkal is an EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC.. Recent SEC Form 4 filings include 0 buys and 41 sells.
Estimated insider holdings value: $6.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 2,103 | $230.99 | $485,773.38 | -1.0% | +13.2% | +34.1% | |
| Feb 28, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sale+OE | 574 | $155.30 | $89,144.57 | -1.3% | -3.3% | +52.7% | |
| Feb 16, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 1,308 | $148.06 | $193,665.96 | -5.4% | +2.9% | +74.5% | |
| Aug 7, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 7,627 | $184.78 | $1,409,305.89 | -9.8% | -9.3% | +42.5% | |
| Apr 28, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sell | 4,294 | $197.12 | $846,449.96 | -5.8% | -2.2% | -28.1% | |
| Mar 3, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | CMO &EVP Dev &Med Affairs | Sale+OE | 18,072 | $200.00 | $3,614,400.00 | -80.6% | -6.9% | -24.7% |